Anika Therapeutics, Inc.ANIKNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank36
5Y CAGR-53.5%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-53.5%/yr
Long-term compound
Percentile
P36
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 0.88% |
| 2024 | 17.37% |
| 2023 | 18.79% |
| 2022 | -32.96% |
| 2021 | 16.63% |
| 2020 | 40.60% |
| 2019 | -8.38% |
| 2018 | -3.18% |
| 2017 | 75.06% |
| 2016 | 19.42% |